CRG appoints Brauer as scientific director

The Curry Rockefeller Group has appointed Lisa Brauer as scientific director. She will report to Linnea Elliott, vice president, editorial director.
Brauer retains part-time appointments as an adjunct associate professor of psychiatry (Neuroscience Research) and as a member of the medical sciences Institutional Review Board (IRB) at the University of Minnesota.
Chuck Rockefeller, chief executive of the company said, "Dr. Brauer brings an impressive capability to CRG with her scientific background and impeccable writing skills. She will be a tremendous resource to us and our clients."
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.